Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer
NCT01228734Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2010
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by Merck KGaA. Started Sep 2010; status: completed.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01228734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01228734.